MedPath

Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Phase 1
Active, not recruiting
Conditions
Acute Lymphoblastic Leukemia, in Relapse
Acute Lymphoblastic Leukemia, Refractory
Interventions
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna
Device: CliniMACS
Biological: CD19- specific CAR engineered autologous T-cells (SJCAR19 product)
First Posted Date
2018-06-29
Last Posted Date
2024-10-30
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
24
Registration Number
NCT03573700
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

First Posted Date
2018-06-27
Last Posted Date
2024-12-20
Lead Sponsor
University of Chicago
Target Recruit Count
15
Registration Number
NCT03571321
Locations
🇺🇸

University of Chicago Medical Center, Chicago, Illinois, United States

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL

Phase 2
Conditions
Leukemia
Adult Lymphoblastic Lymphoma
Adult Acute Lymphoblastic Leukemia
Leukemia, Lymphoblastic
Leukemia, T Cell
Lymphoblastic Lymphoma
Leukemia, Acute
Lymphoblastic Leukemia
Interventions
Drug: Dexamethasone
Drug: vincristine
Drug: Cyclophosphamide
Drug: Idarubicin
Drug: Pegaspargase
Drug: Adriamycin
Drug: Methotrexate
Drug: 6-mercaptopurine.
Drug: Etoposide
Drug: Cytarabine
Procedure: Bone marrow aspiration
Procedure: Intrathecal injection
Radiation: Radiation therapy
Genetic: NGS
Procedure: allogeneic hematopoietic stem cell transplantation
Diagnostic Test: Flow-MRD
Diagnostic Test: FISH
Diagnostic Test: Flow immunophenotyping
Diagnostic Test: Karyotyping
Drug: Chidamide
Diagnostic Test: PET-CT scan
First Posted Date
2018-06-21
Last Posted Date
2018-06-21
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
80
Registration Number
NCT03564704
Locations
🇨🇳

Department of Hematology, Nanfang Hospital, Guangzhou, Guangdong, China

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Phase 2
Withdrawn
Conditions
Metastatic Pancreatic Cancer
Interventions
Drug: Gemcitabine
Drug: Aldoxorubicin HCl
Drug: Nab-paclitaxel
Biological: ALT-803
Biological: ETBX-011
Biological: ETBX-021
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-4000
Biological: GI-6207
Biological: GI-6301
Biological: haNK
Drug: Avelumab
Drug: Bevacizumab
Drug: Capecitabine
Drug: Cyclophosphamide
Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin
First Posted Date
2018-06-20
Last Posted Date
2021-03-18
Lead Sponsor
ImmunityBio, Inc.
Registration Number
NCT03563144
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

First Posted Date
2018-06-20
Last Posted Date
2024-12-11
Lead Sponsor
ImmunityBio, Inc.
Target Recruit Count
2
Registration Number
NCT03563157
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

Phase 1
Withdrawn
Conditions
Hepatocellular Carcinoma Recurrent
Hepatocellular Carcinoma Non-resectable
Interventions
Biological: ETBX-011
Biological: GI-4000
Biological: haNK for infusion
Biological: avelumab
Drug: Capecitabine
Drug: Cyclophosphamide
Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: nab-Paclitaxel
Drug: Sorafenib
Procedure: SBRT
Biological: Aldoxorubicin hydrochloride
Biological: ETBX-051
Biological: ETBX-061
Biological: GI-6207
Biological: GI-6301
Drug: Cetuximab
Biological: N-803
First Posted Date
2018-06-20
Last Posted Date
2021-03-18
Lead Sponsor
ImmunityBio, Inc.
Registration Number
NCT03563170
Locations
🇺🇸

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

Phase 3
Completed
Conditions
Stage II Breast Cancer
Stage IIIA Breast Cancer
Breast Cancer
Breast Neoplasms
HER2-positive Breast Cancer
Interventions
Biological: Herceptin®
Biological: TX05 (trastuzumab)
Drug: Paclitaxel
Drug: Epirubicin
Drug: Cyclophosphamide
First Posted Date
2018-06-14
Last Posted Date
2022-01-14
Lead Sponsor
Tanvex BioPharma USA, Inc.
Target Recruit Count
809
Registration Number
NCT03556358
Locations
🇨🇱

Tanvex Investigational Site 4002, Viña Del Mar, Chile

🇧🇾

Tanvex Investigational Site 1007, Babruysk, Mogilev Region, Belarus

🇧🇾

Tanvex Investigational Site 1008, Lesnoy, Minsk Region, Belarus

and more 143 locations

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

Recruiting
Conditions
Leukemia, Other
Leukemia, Not Otherwise Specified
Interventions
Drug: Cyclophosphamide
Other: Specimen collection
First Posted Date
2018-06-14
Last Posted Date
2024-08-01
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
120
Registration Number
NCT03555851
Locations
🇺🇸

Levine Cancer Institute, Charlotte, North Carolina, United States

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

First Posted Date
2018-06-12
Last Posted Date
2018-06-12
Lead Sponsor
Southwest Hospital, China
Target Recruit Count
100
Registration Number
NCT03553537

Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL

Phase 2
Conditions
Leukemia, Acute
Leukemia, T Cell
Leukemia, Lymphoblastic
Interventions
Drug: Chidamide
Drug: Dexamethasone
Drug: vincristine
Drug: Cyclophosphamide
Drug: Idarubicin
Drug: Pegaspargase
Drug: Adriamycin
Drug: Methotrexate
Drug: 6-Mercaptopurine
Drug: Etoposide
Drug: Cytarabine
Procedure: Bone marrow aspiration
Procedure: Intrathecal injection
Radiation: Radiation therapy
Genetic: NGS
Procedure: allogeneic hematopoietic stem cell transplantation
Diagnostic Test: Flow-MRD
Diagnostic Test: FISH
Diagnostic Test: Flow immunophenotyping
Diagnostic Test: Karyotyping
First Posted Date
2018-06-12
Last Posted Date
2018-06-12
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
70
Registration Number
NCT03553238
Locations
🇨🇳

Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath